VERAVera Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$315M
- 89% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $26M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Operating income | −$34M | −$91M | −$102M | −$167M | −$315M | 89% |
| Net income | −$33M | −$89M | −$96M | −$152M | −$300M | 97% |
| Operating cash flow | −$24M | −$68M | −$92M | −$135M | −$241M | 79% |
| Capex | $0 | $62K | $63K | $972K | $630K | 35% |
| Stock-based comp | $3M | $9M | $11M | $21M | $38M | 82% |
| Buybacks | — | — | $0 | $13K | $0 | 100% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 4
- Net
- −$2M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $7M | $9M | 262 | 137 |
| FY2024 | $6M | $31M | 219 | 103 |
| FY2023 | $3M | $2M | 79 | 105 |